JP2001505995A - 肝細胞成長因子アンタゴニスト - Google Patents

肝細胞成長因子アンタゴニスト

Info

Publication number
JP2001505995A
JP2001505995A JP52162598A JP52162598A JP2001505995A JP 2001505995 A JP2001505995 A JP 2001505995A JP 52162598 A JP52162598 A JP 52162598A JP 52162598 A JP52162598 A JP 52162598A JP 2001505995 A JP2001505995 A JP 2001505995A
Authority
JP
Japan
Prior art keywords
hgf
cells
antagonist
test compound
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP52162598A
Other languages
English (en)
Japanese (ja)
Inventor
ブルックス，デイビッド・パトリック
レイピング，ニコラス・ジェイムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2001505995A publication Critical patent/JP2001505995A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP52162598A 1996-11-05 1997-11-03 肝細胞成長因子アンタゴニスト Pending JP2001505995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3034296P 1996-11-05 1996-11-05
US60/030,342 1996-11-05
PCT/US1997/019891 WO1998019696A1 (en) 1996-11-05 1997-11-03 Hepatocyte growth factor antagonists

Publications (1)

Publication Number Publication Date
JP2001505995A true JP2001505995A (ja) 2001-05-08

Family

ID=21853771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52162598A Pending JP2001505995A (ja) 1996-11-05 1997-11-03 肝細胞成長因子アンタゴニスト

Country Status (4)

Country Link
EP (1) EP0941111A4 (de)
JP (1) JP2001505995A (de)
CA (1) CA2270867A1 (de)
WO (1) WO1998019696A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034650A1 (en) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
RU2403261C2 (ru) 2005-04-15 2010-11-10 Дженентек, Инк. Варианты бета-цепи hgf

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650292B2 (en) * 1990-09-14 1994-06-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A non-mitogenic competitive HGF antagonist
JPH07508420A (ja) * 1992-05-18 1995-09-21 ジェネンテク，インコーポレイテッド 肝細胞成長因子変異体
DE69315440T2 (de) * 1992-09-18 1998-07-09 Us Gov Health & Human Serv Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies

Also Published As

Publication number Publication date
CA2270867A1 (en) 1998-05-14
WO1998019696A1 (en) 1998-05-14
EP0941111A4 (de) 2000-09-27
EP0941111A1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
US7727536B2 (en) EG-VEGF nucleic acids and polypeptides and methods of use
US7736645B2 (en) EG-VEGF nucleic acids and polypeptides and methods of use
JP2001520039A (ja) ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
AU2001268714A1 (en) EV-VEGF nucleic acids and polypeptides and methods of use
KR100553300B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
JP2011231113A (ja) 新規抗血管新生剤及びその使用、特には癌の治療における使用
KR20200024263A (ko) 고혈당증의 치료 및 예방을 위한 펩타이드
US20110034383A1 (en) Cxcl12 gamma a chemokine and uses thereof
US6800604B2 (en) Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor
AU2007308716B2 (en) Inhibition of SOX9 function fn the treatment of proteogl ycan-associated pathophysiological conditions
JP2001505995A (ja) 肝細胞成長因子アンタゴニスト
JP2001514883A (ja) ヒトｆｒｉｚｚｌｅｄ様タンパク質
EP1212417A2 (de) Humane interleukin-1 rezeptor assoziierte kinase-3 (irak3)
JP2006525244A (ja) 糖尿病の治療標的としてのインスリン誘導性遺伝子
KR100678523B1 (ko) Pro840 폴리펩티드 아고니스트 또는 길항제의 확인 방법
KR100961345B1 (ko) Ｅｇ-ｖｅｇｆ 핵산 및 폴리펩티드 및 사용 방법
Yokozaki et al. Cloning of a human hepatocyte growth factor/scatter factor transcription variant from a gastric cancer cell line HSC-39.
JP2006166703A (ja) 軟骨分化制御遺伝子
JP2006166704A (ja) 軟骨分化抑制遺伝子
MXPA02002491A (es) Acidos nucleicos y polipeptidos del factor 19 de crecimiento de fibroblastos y metodos de uso para tratamiento de la obesidad.